Myriad Genetics is a molecular diagnostics company that develops and sells genetic tests to help patients and physicians understand disease risk, guide treatment, and monitor disease. Myriad sells tests primarily to healthcare providers — oncologists, OB/GYNs, urologists, and psychiatrists — through a direct sales force covering roughly 55,000 providers across the U.S., with particular strength in community medicine settings. Myriad also sells internationally through distributors in Japan, Europe, and Asia-Pacific. Myriad's core focus is the Cancer Care Continuum, anchored by MyRisk (a hereditary cancer risk test across 11 cancer types), BRACAnalysis CDx and MyChoice CDx (FDA-approved companion diagnostics guiding PARP inhibitor therapy), and Prolaris (a prostate cancer aggressiveness test). Myriad also offers Precise MRD, an early-stage liquid biopsy test for detecting residual cancer, which is currently in early commercial launch pending reimbursement coverage. In prenatal health, Myriad sells Prequel (non-invasive prenatal screening) and Foresight (carrier screening), and is launching FirstGene, a combined 4-in-1 prenatal screen. In mental health, Myriad sells GeneSight, a pharmacogenomics test used by over 38,000 clinicians to guide psychiatric medication selection. Revenue is driven by test volume and reimbursement rates, with roughly 61% of revenue from commercial insurers. Gross margins are high, reflecting low incremental cost per test once lab infrastructure is in place.